Stereoselective metabolism of cisapride and enantiomer-enantiomer interaction in human cytochrome P450 enzymes: major role of CYP3A
- PMID:11454912
Stereoselective metabolism of cisapride and enantiomer-enantiomer interaction in human cytochrome P450 enzymes: major role of CYP3A
Abstract
Cisapride is a chiral molecule that is marketed as a racemate consisting of two optical isomers, but little is known about its stereoselective metabolism. Studies with (-)-, (+)-, and (+/-)-cisapride were undertaken in human liver microsomes (HLMs) and recombinant cytochrome P450s (P450s) to determine the stereoselective metabolism and enantiomer-enantiomer interaction. Each enantiomer and racemic cisapride were N-dealkylated to norcisapride (NORCIS) and hydroxylated to 3-fluoro-4-hydroxycisapride (3-F-4-OHCIS) and 4-fluoro-2-hydroxycisapride (4-F-2-OHCIS). The kinetics for the formation of NORCIS from (-)-cisapride (Km = 11.9 +/- 4.8 microM; Vmax = 203 +/- 167 pmol/min/mg of protein) or (+)-cisapride (Km = 18.5 +/- 4.7 microM; Vmax = 364 +/- 284 pmol/min/mg of protein) in HLMs exhibited simple Michaelis-Menten kinetics, while a sigmoidal model characterized those of 3-F-4-OHCIS and 4-F-2-OHCIS. In vitro, NORCIS appears to be the major metabolite of both enantiomers. NORCIS and 3-F-4-OHCIS were preferentially formed from (+)-cisapride rather than (-)-cisapride, but that of 4-F-2-OHCIS was the reverse, suggesting regio- and stereoselective metabolism. The formation rate of each metabolite from each enantiomer (20 microM) in 18 HLMs was highly variable (e.g., NORCIS, >35-fold) and correlated with the activity of CYP3A (r = 0.6-0.85; p < 0.05). Coincubation of troleandomycin (50 microM) with cisapride enantiomers (15 microM) in HLMs resulted in potent inhibition of NORCIS formation (by 75-80%), while other inhibitors showed negligible effect. Of 10 recombinant human P450s tested, CYP3A4 catalyzed the formation of NORCIS, 3-F-4-OHCIS, and 4-F-2-OHCIS from each enantiomer and racemic cisapride (15 microM) with the highest specific activity (Km values close to those in HLMs). We noted that the rate of racemic cisapride metabolism by HLMs and recombinant human CYP3A4 is slower compared with equimolar concentrations of each enantiomer. When incubated simultaneously in HLMs, the enantiomers inhibit each other's metabolism. In conclusion, our data demonstrate for the first time the stereoselective metabolism and enantiomer-enantiomer interaction of cisapride. Provided that the potency or the response of the enantiomers differ, understanding the factors that control their disposition as opposed to that of racemic cisapride may better predict adverse drug interactions and the resulting prokinetic efficacy and cardiac safety of cisapride.
Similar articles
- Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies.Desta Z, Soukhova N, Mahal SK, Flockhart DA.Desta Z, et al.Drug Metab Dispos. 2000 Jul;28(7):789-800.Drug Metab Dispos. 2000.PMID:10859153
- Cytochrome P450 Involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms.Pearce RE, Gotschall RR, Kearns GL, Leeder JS.Pearce RE, et al.Drug Metab Dispos. 2001 Dec;29(12):1548-54.Drug Metab Dispos. 2001.PMID:11717173
- Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.Niwa T, Shiraga T, Mitani Y, Terakawa M, Tokuma Y, Kagayama A.Niwa T, et al.Drug Metab Dispos. 2000 Sep;28(9):1128-34.Drug Metab Dispos. 2000.PMID:10950860
- Factors affecting the clinical development of cytochrome p450 3A substrates.Gibbs MA, Hosea NA.Gibbs MA, et al.Clin Pharmacokinet. 2003;42(11):969-84. doi: 10.2165/00003088-200342110-00003.Clin Pharmacokinet. 2003.PMID:12908853Review.
- Stereoselective and isozyme-selective drug interactions.Gibaldi M.Gibaldi M.Chirality. 1993;5(6):407-13. doi: 10.1002/chir.530050603.Chirality. 1993.PMID:8398598Review.
Cited by
- Metabolism of 4-Aminopiperidine Drugs by Cytochrome P450s: Molecular and Quantum Mechanical Insights into Drug Design.Sun H, Scott DO.Sun H, et al.ACS Med Chem Lett. 2011 Aug 11;2(8):638-643. doi: 10.1021/ml200117z. Epub 2011 Jun 18.ACS Med Chem Lett. 2011.PMID:21841964Free PMC article.
- Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children.Johnson TN, Rostami-Hodjegan A, Tucker GT.Johnson TN, et al.Clin Pharmacokinet. 2006;45(9):931-56. doi: 10.2165/00003088-200645090-00005.Clin Pharmacokinet. 2006.PMID:16928154
- Chiral metabolism of propafenone in rat hepatic microsomes treated with two inducers.Zhou Q, Yao TW, Zeng S.Zhou Q, et al.World J Gastroenterol. 2001 Dec;7(6):830-5. doi: 10.3748/wjg.v7.i6.830.World J Gastroenterol. 2001.PMID:11854911Free PMC article.
- Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice.Desta Z, Kivistö KT, Lilja JJ, Backman JT, Soukhova N, Neuvonen PJ, Flockhart DA.Desta Z, et al.Br J Clin Pharmacol. 2001 Oct;52(4):399-407. doi: 10.1046/j.0306-5251.2001.01473.x.Br J Clin Pharmacol. 2001.PMID:11678783Free PMC article.Clinical Trial.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Other Literature Sources